BioWorld - Wednesday, December 14, 2022
Breaking News: Try BioWorld for escaped for 2 weeksSee today's BioWorld ScienceHome » Jing Medicine Technology discloses caller PROTACs for cancer
Cancer
Jing Medicine Technology (Shanghai) Ltd. has patented proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to ALK tyrosine kinase receptor- and/or epidermal maturation origin receptor (EGFR)- and/or proto-oncogene tyrosine-protein kinase ROS (ROS1)-targeting moiety reported to beryllium utile for the attraction of cancer.
English (US)